1340P Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study

D Zhang,X Gao,W Zhong,M Chen,Y Shi,D Zhao,X Liu,J Zhao,F Shen,M Wang,H Zhang,Y Xu,J Liu

doi:10.1016/j.annonc.2023.09.2373

1340P Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study

D Zhang, X Gao + Show 11 more

https://doi.org/10.1016/j.annonc.2023.09.2373

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Oct 1, 2023

#First-generation EGFR Tyrosine Kinase Inhibitors #Real-world Cohort Study + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1340P Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study

Full Text